Pfizer Inc (NYSE:PFE) – French biotech Cellectis surges as Pfizer signs cancer drug deal

[Reuters] – * Pfizer secures access to early cancer-hunting CAR-T drugs * Cellectis gets $80 mln upfront, shares soar 50 percent (Adds details on rival Novartis research, more on technology, Cellectis valuation) June . . . → Read More: Pfizer Inc (NYSE:PFE) – French biotech Cellectis surges as Pfizer signs cancer drug deal Similar Articles: Market Update: Pfizer Inc (NYSE:PFE) – AstraZeneca in partnering talks for Alzheimer’s drug Pfizer Inc (NYSE:PFE) – Pfizer chasing AstraZeneca for potential $100 bln deal Stock Update: Pfizer Inc (NYSE:PFE) – Pfizer lung cancer drug fails in two large studies
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.